OOIR: Observatory of International Research

Papers

(The TQCC of Annual Review of Pharmacology and Toxicology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays	140
Introduction to the Theme “New Approaches, Technology, and Techniques That Advance Pharmacology and Toxicology”	140
How Biologics Have Changed the Drug Discovery Landscape	139
The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases	138
Pharmacology of Intestinal Inflammation and Repair	136
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease	126
Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets	104
Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology	96
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities	96
Evolving Approaches for Pharmacological Therapy of Obesity	82
Introduction to the Theme “Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment”	79
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development	77
Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?	75
	72
E-Cigarette Toxicology	72
Introduction to the Theme “Development of New Drugs: Moving from the Bench to Bedside and Improved Patient Care”	69
Community Aspects of HIV Biomedical Prevention	68
Incretin Signaling Neighborhoods and Adverse Drug Reactions	68
Multisystem Toxicity of E-Cigarettes in Preclinical and Clinical Studies: Pathophysiologic Effects of E-Cigarette Aerosol Exposures from Head to Toe	67
The Gut Microbiome, Metformin, and Aging	66
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer	66
Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss	66
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges	60
Endocannabinoid-Based Therapies	60
Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases	59

Gβγ Signaling: Lessons Across the Cellular Multiverse	57
G Protein–Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders	57
OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory	56
GPCR Biosensors to Study Conformational Dynamics and Signaling in Drug Discovery	55
Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies	52
Health Digital Twins in Life Science and Health Care Innovation	52
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon	51
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation	50
Synthetic Cannabinoids: A Pharmacological and Toxicological Overview	50
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment	47
RNA Splicing as a Therapeutic Target in Cancer	47
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy	40
Pharmacogenetics of Antiplatelet Therapy	39